{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:11:49Z","timestamp":1790741509653,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82472016"],"award-info":[{"award-number":["No. 82472016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Health Commission of Sichuan Province Medical Science and Technology Program","award":["24QNMP016"],"award-info":[{"award-number":["24QNMP016"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      This exploratory study aimed to assess the prognostic value of quantitative parameters derived from [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAP-2286 PET\/CT in predicting treatment response to [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-FAP-2286 radioligand therapy in patients with non-small cell lung cancer (NSCLC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      Patients with histologically confirmed NSCLC underwent [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAP-2286 PET\/CT before and after 2 cycles of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-FAP-2286 therapy. Based on clinical outcomes, patients were classified as responders or nonresponders. Quantitative PET\/CT parameters\u2014including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), FAPI-avid tumor volume (FTV), total lesion FAP expression (TLF), and tumor-to-background ratio (TBR)\u2014were evaluated. Progression-free survival (PFS) and overall survival (OS) were compared using the Kaplan-Meier method and log-rank test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In this cohort of 18 NSCLC patients, baseline PET parameters, including FTV, TLF, and TBR, were significant predictors. Interval PET parameters, such as SUVmax, FTV, TLF, and TBR, were significant predictors of treatment response. In addition, \u0394PET parameters \u0394SUVmax, \u0394FTV, and \u0394TLF also correlated with therapeutic outcomes. The responder group had a median progression-free survival (mPFS) of 14.4 months, while the nonresponder group had an mPFS of 7.15 months. The OS for the responder group was not reached, whereas the nonresponder group exhibited an OS of 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Quantitative parameters derived from [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAP-2286 PET\/CT are valuable predictors of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-FAP-2286 treatment efficacy in NSCLC patients. Dynamic monitoring of these metrics allows for early identification of treatment responses and supports personalized therapy strategies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006210","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T17:00:06Z","timestamp":1765213206000},"page":"108-114","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Exploratory Analysis of [68Ga]Ga-FAP-2286 PET\/CT Quantitative Parameters for Predicting Response to [177Lu]Lu-FAP-2286 Therapy in Non-small Cell Lung Cancer"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-5768","authenticated-orcid":false,"given":"Min","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranositics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine"},{"name":"Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranositics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranositics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranositics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Magnetic Resonance Imaging, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4088-7649","authenticated-orcid":false,"given":"Yue","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranositics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"R1-20260107","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.3390\/cells11203200","article-title":"Biomarker-targeted therapies in non-small cell lung cancer: current status and perspectives","volume":"11","author":"Guo","year":"2022","journal-title":"Cells"},{"key":"R2-20260107","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ymthe.2022.11.011","article-title":"PROTAC therapy as a new targeted therapy for lung cancer","volume":"3","author":"Li","year":"2023","journal-title":"Mol Ther"},{"key":"R3-20260107","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev-med-042915-102442","article-title":"The end of nihilism: systemic therapy of advanced non-small cell lung cancer","volume":"68","author":"Ernani","year":"2017","journal-title":"Annu Rev Med"},{"key":"R4-20260107","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoncol.2023.1891","article-title":"Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer","volume":"8","author":"Sun","year":"2023","journal-title":"JAMA Oncol"},{"key":"R5-20260107","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1038\/s41467-022-34395-2","article-title":"Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment","volume":"1","author":"Luo","year":"2022","journal-title":"Nat Commun"},{"key":"R6-20260107","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"6","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"R7-20260107","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health and malignancy","volume":"3","author":"Fitzgerald","year":"2020","journal-title":"Cancer Metastasis Reviews"},{"key":"R8-20260107","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"11","author":"Zboralski","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R9-20260107","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/1874471013666191223151402","article-title":"Alternative and new radiopharmaceutical agents for lung cancer","volume":"3","author":"Telo","year":"2020","journal-title":"Curr Radiopharm"},{"key":"R10-20260107","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1148\/rg.2018180060","article-title":"Role of FDG PET\/CT in the eighth edition of TNM staging of non-small cell lung cancer","volume":"7","author":"Kandathil","year":"2018","journal-title":"Radiographics"},{"key":"R11-20260107","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1007\/s00259-022-05818-5","article-title":"Higher accuracy of [(68) Ga]Ga-DOTA-FAPI-04 PET\/CT comparing with 2-[(18)F]FDG PET\/CT in clinical staging of NSCLC","volume":"8","author":"Zhou","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-20260107","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/RLU.0000000000004881","article-title":"68 Ga-LNC-1007 PET\/CT imaging in a patient with renal cell carcinoma compared with 68 Ga-PSMA-11 PET\/CT","volume":"12","author":"Lin","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R13-20260107","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3390\/diagnostics13122018","article-title":"FAPI PET\/CT imaging-an updated review","volume":"13","author":"Chandekar","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R14-20260107","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/RLU.0000000000005297","article-title":"Efficacy and safety evaluation of 177Lu-FAP-2286 in the treatment of advanced lung cancer","volume":"9","author":"Xie","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R15-20260107","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","article-title":"Feasibility and therapeutic potential of [(177)Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma","volume":"1","author":"Banihashemian","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R16-20260107","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: first-in-humans results","volume":"3","author":"Baum","year":"2022","journal-title":"J Nucl Med"},{"key":"R17-20260107","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/RLU.0000000000005489","article-title":"177 Lu-FAP-2286 therapy in a case of squamous lung cancer","volume":"1","author":"Li","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R18-20260107","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1007\/s00259-022-05754-4","article-title":"Expression of fibroblast activation protein in lung cancer and its correlation with tumor glucose metabolism and histopathology","volume":"8","author":"Chen","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R19-20260107","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"9","author":"Loktev","year":"2018","journal-title":"J Nucl Med"},{"key":"R20-20260107","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s00259-022-06048-5","article-title":"[(177)Lu]Lu-FAP-2286 therapy in a case of right lung squamous cell carcinoma with systemic metastases","volume":"4","author":"Rao","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-20260107","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","article-title":"FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling","volume":"14","author":"Yang","year":"2016","journal-title":"Cancer Res"},{"key":"R22-20260107","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1126\/science.1195300","article-title":"Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha","volume":"6005","author":"Kraman","year":"2010","journal-title":"Science"},{"key":"R23-20260107","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3727\/096504016X14768383625385","article-title":"Fibroblast activation protein-\u03b1-positive fibroblasts promote gastric cancer progression and resistance to immune checkpoint blockade","volume":"4","author":"Wen","year":"2017","journal-title":"Oncol Res"},{"key":"R24-20260107","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-14-3041","article-title":"Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells","volume":"14","author":"Lo","year":"2015","journal-title":"Cancer Res"},{"key":"R25-20260107","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1172\/JCI26532","article-title":"Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake","volume":"7","author":"Loeffler","year":"2006","journal-title":"J Clin Invest"},{"key":"R26-20260107","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2967\/jnumed.123.266806","article-title":"68Ga-FAPI-04 PET\/CT in non-small cell lung cancer: accurate evaluation of lymph node metastasis and correlation with fibroblast activation protein expression","volume":"4","author":"Li","year":"2024","journal-title":"J Nucl Med"},{"key":"R27-20260107","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and therapeutic potential of 177Lu-fibroblast activation protein inhibitor-46 for patients with relapsed or refractory cancers: a preliminary study","volume":"11","author":"Assadi","year":"2021","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T19:00:12Z","timestamp":1767812412000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006210","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"2025-06-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}